Review Reports
- Ahmed A. H. Abdellatif 1,*,
- Hesham M. Tawfeek 2,3 and
- Mahmoud A. Younis 2,*
- et al.
Reviewer 1: Lubov Snegur Reviewer 2: Sauradip Chaudhuri Reviewer 3: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsPharmaceutics_2026_4525221
The manuscript entitled ‘Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy’ by Ahmed A H Abddelatif, Hesham M. Tawfeek, Mahmoud Zaki El-Readi, Amani E. Alharbi, Hamzah Maswadeh, Mohammed A Amin, Safaa Yehia Eid, Abousree T. Ellethy, Bassem Refaat, Akhmed Aslam, Waleed M. Altowayan, and Mahmoud A. Younis, represents an article.
The authors proposed an interesting manuscript on the pharmaceutical benefits of co-solubilization of paclitaxel and docetaxel for synergistic anticancer chemotherapy. It should be noted that paclitaxel is a plant-based anticancer agent, and docetaxel is an anticancer agent, a semi-synthetic analogue of paclitaxel.
Electrospray ionization mass spectrometry (ESI-MS) and high-performance liquid chromatography (HPLC) were used to confirm the successful formation of the formulation and the inclusion of all its components.
To test the anticancer activity, colorectal carcinoma cell lines HT29, SW480, and SW62 were used compared with normal fibroblast cell line, MCR-5.
Additionaly, a synergistic anticancer activity of paclitaxel and docetaxel was demonstrated by the novel formulation, leading to cell cycle arrest at low drug concentrations.
Furthermore, Molecular-based mechanistic investigations confirmed the induced cell cycle arrest via suppression of the cell cycle drivers CDK2 and Cyclin A.
These materials could be useful to specialists in the field of medicinal chemistry and pharmacology. They will also be of interest to biochemists and chemists working with bioactive compounds.
The manuscript does not raise any objections, the research materials are presented in large quantities flawlessly and can be published in ’Pharmaceutics’.
Several inaccuracies should be noted.
- The conclusions are well presented, however I think the abbreviations should be clarified.
- An overly used abbreviation makes the manuscript difficult to read.
Author Response
We are thankful to all the thoughtful and helpful comments raised by the reviewers and editors during the thorough review of the initial version of our manuscript, which helped us to significantly improve the quality of our work.
In the present revision, we have performed a thorough major revision of our manuscript in lights of the reviewers' recommendations. All the changes have been highlighted in the revised text. Below, is a point-by-point response to the reviewers' comments.
#Reviewer 1
The manuscript entitled ‘Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy’ by Ahmed A H Abddelatif, Hesham M. Tawfeek, Mahmoud Zaki El-Readi, Amani E. Alharbi, Hamzah Maswadeh, Mohammed A Amin, Safaa Yehia Eid, Abousree T. Ellethy, Bassem Refaat, Akhmed Aslam, Waleed M. Altowayan, and Mahmoud A. Younis, represents an article.
The authors proposed an interesting manuscript on the pharmaceutical benefits of co-solubilization of paclitaxel and docetaxel for synergistic anticancer chemotherapy. It should be noted that paclitaxel is a plant-based anticancer agent, and docetaxel is an anticancer agent, a semi-synthetic analogue of paclitaxel.
Electrospray ionization mass spectrometry (ESI-MS) and high-performance liquid chromatography (HPLC) were used to confirm the successful formation of the formulation and the inclusion of all its components.
To test the anticancer activity, colorectal carcinoma cell lines HT29, SW480, and SW62 were used compared with normal fibroblast cell line, MCR-5.
Additionally, a synergistic anticancer activity of paclitaxel and docetaxel was demonstrated by the novel formulation, leading to cell cycle arrest at low drug concentrations.
Furthermore, Molecular-based mechanistic investigations confirmed the induced cell cycle arrest via suppression of the cell cycle drivers CDK2 and Cyclin A.
These materials could be useful to specialists in the field of medicinal chemistry and pharmacology. They will also be of interest to biochemists and chemists working with bioactive compounds.
The manuscript does not raise any objections; the research materials are presented in large quantities flawlessly and can be published in ’Pharmaceutics’.
We sincerely thank the reviewer for the positive and encouraging evaluation of our manuscript. We greatly appreciate the reviewer’s recognition of the potential pharmaceutical and pharmacological significance of the proposed formulation and its anticancer activity. We have attempted to further improve the quality of our manuscript in lights of the reviewer's recommendations.
Several inaccuracies should be noted.
- The conclusions are well presented; however, I think the abbreviations should be clarified.
Thank you for this helpful suggestion. We agree that abbreviations should be clearly defined to improve readability. Accordingly, we have revised the manuscript to ensure that all abbreviations are defined at their first occurrence in the main text. In particular, abbreviations such as paclitaxel (PTX), docetaxel (DTX), octreotide (OCT), high-performance liquid chromatography (HPLC), electrospray ionization mass spectrometry (ESI-MS), and other technical abbreviations are now clearly introduced before their subsequent use. We have also checked the Abstract, Results, Discussion, and Conclusion sections to ensure consistent terminology.
- An overly used abbreviation makes the manuscript difficult to read.
We appreciate this important comment and agree that excessive use of abbreviations may reduce readability. We have therefore carefully revised the manuscript to minimize unnecessary repetition of abbreviations. Abbreviations are now primarily used where repeated terminology would otherwise make the text cumbersome, while frequently recurring abbreviations have been retained for consistency. We have also replaced some abbreviations with the full terms where this improves readability, particularly in narrative sections and the Conclusion.
Reviewer 2 Report
Comments and Suggestions for AuthorsThe manuscript describes the development and biological activity of a novel octreotide functionalized targeted nanomedicine of combined paclitaxel and docetaxel. While there is enough evidence of potency and active targeting of cancer cell lines in-vitro (HT29, SW480 & SW620), no in-vivo data is presented as a proof of concept for translational scalability. The authors also present evidence of synergistic effect of the two drugs. Considering the overall data, the manuscript is worthy of being accepted in its present form for publication without further additional experiments or revision.
- The study investigates whether octreotide (OCT) can simultaneously solubilize and facilitate targeted delivery of paclitaxel (PTX) and docetaxel (DTX), producing a simple formulation with enhanced and synergistic anticancer activity. The authors evaluate OCT-PTX-DTX through physicochemical characterization, cytotoxicity in colorectal cancer cells, drug-synergy analysis, cell-cycle effects, and gene-expression studies. The question is clearly relevant to overcoming the poor aqueous solubility and limited tumor selectivity associated with conventional taxane formulations.
-
The topic is relevant and potentially original. OCT-mediated tumor targeting itself is established, but using OCT as a dual-purpose solubilizing and targeting component for simultaneous PTX/DTX delivery appears to provide the principal novelty. The approach may address the complexity associated with conventional targeted nanocarriers.
-
The manuscript provides interesting in-vitro proof of concept for a relatively simple OCT-assisted PTX/DTX formulation. It demonstrates anticancer activity across three colorectal cancer cell lines and reports PTX/DTX synergism, with CI values of approximately 0.4–0.5. The combination of formulation development, cytotoxicity, cell-cycle analysis, and molecular measurements is a strength. Nevertheless, its principal demonstrated contribution is enhanced in-vitro pharmacological activity; targeted delivery and translational advantages remain less firmly established.
-
Several improvements are recommended. Direct evidence of SSTR-mediated uptake should be obtained using receptor competition/blocking, SSTR knockdown, or quantitative cellular uptake studies. A matched free PTX+DTX combination at the same molar ratio is an important missing control. Quantitative drug content/recovery, solubility enhancement, zeta potential, stability, and release studies should also be provided.
-
The conclusions are partially supported. The results support formation of OCT-PTX-DTX and promising in-vitro cytotoxicity, PTX/DTX synergism, cell-cycle alterations, and associated gene-expression changes. However, increased SSTR1/SSTR2 expression does not establish receptor-mediated internalization. Similarly, claims of clinical translatability and higher tolerability than commercial formulations are premature without in-vivo pharmacokinetic, biodistribution, efficacy, or toxicity studies. The conclusions should therefore emphasize an in-vitro proof of concept and identify targeting, safety, and clinical translation as subjects for future investigation.
-
The references are generally appropriate and cover taxane pharmacology/formulation, OCT targeting, combination therapy, drug-delivery systems, synergy analysis, and cell-cycle mechanisms. References supporting general SSTR biology should also not be used as substitutes for experimental evidence of SSTR-mediated uptake in the present system.
-
The figures generally communicate the results clearly, but several improvements are warranted. Figure 3 should report IC50 confidence intervals. Figure 7's description of “synergistic” gene regulation should be moderated unless formally demonstrated, and Figure 8 should be labeled as a proposed mechanism.
Author Response
The manuscript describes the development and biological activity of a novel octreotide functionalized targeted nanomedicine of combined paclitaxel and docetaxel. While there is enough evidence of potency and active targeting of cancer cell lines in-vitro (HT29, SW480 & SW620), no in-vivo data is presented as a proof of concept for translational scalability. The authors also present evidence of synergistic effect of the two drugs. Considering the overall data, the manuscript is worthy of being accepted in its present form for publication without further additional experiments or revision.
- The study investigates whether octreotide (OCT) can simultaneously solubilize and facilitate targeted delivery of paclitaxel (PTX) and docetaxel (DTX), producing a simple formulation with enhanced and synergistic anticancer activity. The authors evaluate OCT-PTX-DTX through physicochemical characterization, cytotoxicity in colorectal cancer cells, drug-synergy analysis, cell-cycle effects, and gene-expression studies. The question is clearly relevant to overcoming the poor aqueous solubility and limited tumor selectivity associated with conventional taxane formulations.
- The topic is relevant and potentially original. OCT-mediated tumor targeting itself is established, but using OCT as a dual-purpose solubilizing and targeting component for simultaneous PTX/DTX delivery appears to provide the principal novelty. The approach may address the complexity associated with conventional targeted nanocarriers.
- The manuscript provides interesting in-vitro proof of concept for a relatively simple OCT-assisted PTX/DTX formulation. It demonstrates anticancer activity across three colorectal cancer cell lines and reports PTX/DTX synergism, with CI values of approximately 0.4–0.5. The combination of formulation development, cytotoxicity, cell-cycle analysis, and molecular measurements is a strength. Nevertheless, its principal demonstrated contribution is enhanced in-vitro pharmacological activity; targeted delivery and translational advantages remain less firmly established.
We sincerely thank the reviewer for the careful, constructive, and highly positive assessment of our manuscript. We greatly appreciate the recognition of the novelty of using octreotide (OCT) as both a solubilizing and targeting component for the simultaneous delivery of paclitaxel (PTX) and docetaxel (DTX), as well as the recognition of the in vitro proof-of-concept provided by the physicochemical characterization, cytotoxicity studies, synergy analysis, cell-cycle assessment, and molecular investigations.
Several improvements are recommended. Direct evidence of SSTR-mediated uptake should be obtained using receptor competition/blocking, SSTR knockdown, or quantitative cellular uptake studies. A matched free PTX+DTX combination at the same molar ratio is an important missing control. Quantitative drug content/recovery, solubility enhancement, zeta potential, stability, and release studies should also be provided.
We appreciate the reviewer’s comments regarding the distinction between the demonstrated in-vitro findings and the aspects that require further investigation for translational development. In response, we have carefully revised the manuscript to distinguish experimentally demonstrated findings from proposed mechanisms and future translational possibilities. We have also moderated several statements regarding SSTR-mediated targeting, safety, and clinical translation. Importantly, because the present study was designed as an initial in vitro proof-of-concept, we have not performed in-depth molecular and mechanistic investigations at the present level of study. However, further characterization and investigation are planned in our future experiments.
In the present study, SSTR1 and SSTR2 gene expression was evaluated by qRT-PCR, with increased expression observed following treatment. However, we agree that changes in SSTR mRNA expression alone do not establish receptor-mediated cellular internalization. We have therefore revised the relevant statements to describe the findings as consistent with a possible contribution of SSTR-related signaling, rather than definitive evidence of SSTR-mediated uptake. We have stated that further in-depth mechanistic investigations are needed to confirm such a hypothesis.
Regarding the matched free PTX+DTX combination, we agree that this would provide an important control for distinguishing the contribution of OCT-mediated formulation from the intrinsic activity of the two-taxane combination. The present study compared the formulation with the individual agents and OCT-containing conditions, but did not include a separately prepared free PTX+DTX combination at the identical molar ratio. We acknowledge this limitation and we will consider it in our future experiments.
Similarly, we agree that quantitative drug loading/recovery, quantitative solubility enhancement, zeta potential, storage stability, and PTX/DTX release studies would provide important additional evidence for pharmaceutical development. As we explained above, this study has been designed as an in vitro proof-of-concept study, while further characterizations recommended by the reviewer have been identified as priorities for subsequent formulation-development studies.
The conclusions are partially supported. The results support formation of OCT-PTX-DTX and promising in-vitro cytotoxicity, PTX/DTX synergism, cell-cycle alterations, and associated gene-expression changes. However, increased SSTR1/SSTR2 expression does not establish receptor-mediated internalization. Similarly, claims of clinical translatability and higher tolerability than commercial formulations are premature without in-vivo pharmacokinetic, biodistribution, efficacy, or toxicity studies. The conclusions should therefore emphasize an in-vitro proof of concept and identify targeting, safety, and clinical translation as subjects for future investigation.
We completely agree with this assessment and thank the reviewer for highlighting this important distinction.
Accordingly, we have revised the Conclusion to emphasize that the present work provides an in-vitro proof of concept for an OCT-assisted PTX/DTX formulation. We have moderated statements that could imply that clinical translation, superior tolerability, or in-vivo tumor targeting have already been demonstrated.
We also agree that increased SSTR1/SSTR2 expression cannot by itself establish receptor-mediated internalization. The revised manuscript now presents this finding as supportive of a possible SSTR-associated mechanism, while explicitly recognizing that receptor binding, uptake, and functional receptor-dependence require further validation.
We further acknowledge that in-vivo pharmacokinetic, biodistribution, efficacy, and toxicity studies will be required before conclusions regarding translational scalability or comparative tolerability can be drawn.
The references are generally appropriate and cover taxane pharmacology/formulation, OCT targeting, combination therapy, drug-delivery systems, synergy analysis, and cell-cycle mechanisms. References supporting general SSTR biology should also not be used as substitutes for experimental evidence of SSTR-mediated uptake in the present system.
We thank the reviewer for this valuable clarification. We have carefully reviewed the relevant references and revised the text to ensure that literature describing general SSTR biology is used only to provide background and biological rationale. Such references are not presented as experimental evidence that the present OCT-PTX-DTX formulation undergoes SSTR-mediated internalization.
The revised manuscript now clearly separates the established biological background from the mechanistic interpretation generated from our own experimental findings.
The figures generally communicate the results clearly, but several improvements are warranted. Figure 3 should report IC50 confidence intervals. Figure 7's description of “synergistic” gene regulation should be moderated unless formally demonstrated, and Figure 8 should be labeled as a proposed mechanism.
We thank the reviewer for these specific recommendations. For Figure 3, we agree that confidence intervals would provide a more complete representation of the IC50 estimates. The cytotoxicity study used multiple concentrations ranging from 0.1 to 200 nM and included the three colorectal cancer cell lines and the normal fibroblast model. A confidence level of 95% was adopted. *P<0.05, **P<0.01, and ***P<0.001 were assumed to be statistically significant. We have clearly stated these statistical criteria, both in the statistical analyses subsection in the Methods section, as well as in the relevant figure legend.
For Figure 7, we agree that the term “synergistic” should not be applied directly to gene-expression changes because synergy was formally assessed for the pharmacological interaction between PTX and DTX using combination-index analysis. We have therefore moderated the wording to describe the observed gene-expression changes as associated with or consistent with the observed biological response rather than as “synergistic gene regulation.”
For Figure 8, we fully agree and have revised the figure and its legend to clearly identify it as a “proposed mechanism” rather than a demonstrated mechanistic pathway. This change reflects the fact that the present data support associations among OCT treatment, SSTR1/SSTR2 expression, cell-cycle regulators, and the observed phenotype, but do not establish a complete causal pathway.
Author Response File:
Author Response.docx
Reviewer 3 Report
Comments and Suggestions for AuthorsReviewer comments:
This manuscript reports a single-step octreotide-mediated formulation designed to co-solubilize and selectively deliver paclitaxel and docetaxel to colorectal cancer cells. The formulation was characterized by DSC, ESI-MS, HPLC, particle-size analysis, and TEM, and its cytotoxicity, drug interaction, cell-cycle effects, and selected gene-expression changes were evaluated in cancer and fibroblast cell lines. The formulation showed improved in-vitro cytotoxicity compared with the free drugs, however, the current data do not sufficiently establish its structure, receptor-mediated uptake, true pharmacological synergy, or clinical translatability. Further, a preliminary in-vitro formulation study as important physicochemical, mechanistic, pharmacological, and statistical controls are lacking. The manuscript may require major revision based on the below given comments.
Major comments
- Formulation structure and co-solubilization mechanism. ESI-MS and HPLC confirm the presence of OCT, PTX, and DTX but do not prove that the drugs are embedded in an OCT matrix or form a specific molecular complex. The authors consider providing drug-loading efficiency, encapsulation/recovery data, solubility enhancement, mass balance, and complementary analyses such as PXRD, FTIR, Raman spectroscopy, or solid-state NMR.
- Interpretation of DSC data. The disappearance of DSC peaks does not by itself prove amorphization or compatibility, because dilution, overlapping transitions, and reduced detection sensitivity may produce the same result. PXRD and suitable physical-mixture controls are needed, and the authors should revise the statement that the formulation has “no incompatibility” unless supported by additional evidence.
- Discrepancy in particle-size. Laser diffraction showed a median diameter of 0.837 µm, whereas TEM showed particles of approximately 200 nm. The authors should clarify whether this difference results from aggregation, dry-state shrinkage, or different measurement principles and should report dispersion conditions, refractive indices, replicate preparations, and preferably DLS, zeta potential, and stability data.
- Colloidal stability and formulation quality. Visual inspection is insufficient to establish stability of a submicron formulation. Size, polydispersity, zeta potential, drug content, precipitation, pH, residual ethanol, and chemical stability should be evaluated during storage and under physiologically relevant conditions.
- Absence of drug-release data. The manuscript claims improved dissolution and potentially controlled delivery, but no release or dissolution study is provided. Simultaneous PTX and DTX release should be measured in aqueous and physiologically relevant media, with validated quantification and assessment of whether the drug ratio remains constant during release.
- Controls for free-drug comparison. Free PTX and DTX were prepared in DMSO, whereas the formulation was tested in aqueous medium, and the dose basis is not always clear. The authors should use vehicle-matched controls and state whether reported concentrations refer to total taxane, individual drug, or total formulation concentration.
- Lack of evidence for synergism. The reported CI values are insufficient to establish synergy because the dose ratio, effect level, confidence intervals, and full dose–response analysis are not clearly provided. The authors should apply a validated synergy model across multiple effect levels and include PTX+DTX without OCT, OCT+PTX, and OCT+DTX controls.
- Receptor-mediated targeting. Increased SSTR1/2 mRNA does not demonstrate receptor-mediated uptake. The authors should measure surface receptor expression and perform competition with excess OCT, SSTR-antagonist studies, receptor knockdown, and quantitative uptake experiments using labeled particles or analytically measured intracellular drug.
- Proposed positive feedback of SSTR expression. The claim that OCT binding upregulates SSTRs and promotes further internalization is based only on a single qRT-PCR measurement. Time-dependent measurements of surface and total receptor protein, receptor internalization, and functional uptake are required; otherwise, this mechanism should be presented only as a hypothesis.
- Mechanism of cell death. Sub-G1 accumulation and reduced CDK2/Cyclin A transcripts do not definitively demonstrate apoptosis or functional pathway inhibition. Annexin V/PI staining, caspase and PARP analysis, protein-level validation, and appropriate rescue or inhibitor experiments should be added before claiming apoptosis through p53/p21 pathway.
- Cancer selectivity. Selectivity is based on comparison with only one fibroblast cell line, and SSTR expression in the cancer and normal cells was not established. Additional normal cell models and receptor-expression analyses are recommended, while claims of tumor selectivity should otherwise be limited to the tested cell lines.
- Clinical-translational claims. Claims regarding in-vivo tolerability, improved bioavailability, tumor targeting, and clinical translation are not supported by cell-culture data alone. These statements should be removed or substantially changed unless pharmacokinetic, biodistribution, toxicity, hemolysis, and in-vivo efficacy studies are added.
- Rationale for combining two taxanes. PTX and DTX share related mechanisms and may produce overlapping toxicities, so the rationale for their combination requires stronger justification. The authors should explain the selected ratio and compare the dual-drug formulation with optimized single-drug formulations and clinically relevant taxane delivery systems.
- Literature comparison and limitations. The discussion should compare this formulation with established taxane nanocarriers, albumin-bound PTX, polymeric micelles, liposomes, and octreotide-targeted systems. The authors should also explicitly acknowledge the lack of release, uptake, in-vivo, long-term stability, and comprehensive toxicity data.
Minor comments
- The title and abstract should specify that the evidence is based on in-vitro experiments and should avoid implying established clinical translation.
- Verify and consistently use the correct designation of the normal fibroblast line, apparently MRC-5 rather than MCR-5.
- The abstract should report the PTX:DTX:OCT composition, particle-size metric, key IC50 values, and experimental limitations.
- Clarify whether OCT refers to octreotide free base or octreotide acetate and how its counterion is considered in concentration calculations.
- The preparation method should include total volume, evaporation temperature and duration, stirring rate, final pH, final volume, and sterilization or filtration procedures.
- Use “colloidal dispersion” or “dispersion” instead of “solution” if the formulation contains discrete particles.
- Validate the HPLC method for linearity, precision, accuracy, recovery, specificity, detection limits, and stability of all three components.
- The ESI-MS section should report adduct assignments, mass accuracy, calibration, representative spectra, and matrix-effect considerations.
- The disappearance of the DTX ESI-MS peak may result from ion suppression, degradation, or sample-preparation effects and should not be attributed directly to molecular interaction.
- The particle-size section should report the complete distribution, measurement conditions, number of preparations, and reproducibility.
- The proposed sequential drug release from small and large particles is speculative and should be removed or supported by release experiments.
- The MTT assay should include cell-free formulation controls to exclude interference with the tetrazolium reaction or optical-density measurement.
- Include untreated, vehicle, OCT-only, formulation-matrix, and free-drug controls in the cytotoxicity experiments.
- IC50 values should be reported with 95% confidence intervals and goodness-of-fit parameters.
- The selectivity-index calculation should be defined explicitly and should not be interpreted as proof of in-vivo therapeutic selectivity.
- Figure 4 should identify the dose ratio, effect level, and uncertainty associated with each CI value.
Author Response
This manuscript reports a single-step octreotide-mediated formulation designed to co-solubilize and selectively deliver paclitaxel and docetaxel to colorectal cancer cells. The formulation was characterized by DSC, ESI-MS, HPLC, particle-size analysis, and TEM, and its cytotoxicity, drug interaction, cell-cycle effects, and selected gene-expression changes were evaluated in cancer and fibroblast cell lines. The formulation showed improved in-vitro cytotoxicity compared with the free drugs, however, the current data do not sufficiently establish its structure, receptor-mediated uptake, true pharmacological synergy, or clinical translatability. Further, a preliminary in-vitro formulation study as important physicochemical, mechanistic, pharmacological, and statistical controls are lacking. The manuscript may require major revision based on the below given comments.
We sincerely thank the Reviewer for the careful and constructive evaluation of our manuscript. We greatly appreciate the Reviewer’s comments, which have helped us improve the scientific rigor and appropriately define the scope of the present study.
We agree that several mechanistic and physicochemical interpretations in the original manuscript were stated too strongly relative to the experimental evidence available. In the revised manuscript, we have therefore carefully distinguished experimental findings from proposed mechanisms, moderated claims that cannot be conclusively established from the current in vitro data, clarified methodological details, and corrected terminology. Our detailed responses are provided below.
- ESI-MS and HPLC confirm the presence of OCT, PTX, and DTX but do not prove that the drugs are embedded in an OCT matrix or form a specific molecular complex. The authors should consider providing drug-loading efficiency, encapsulation/recovery data, solubility enhancement, mass balance, and complementary analyses such as PXRD, FTIR, Raman spectroscopy, or solid-state NMR.
We thank the Reviewer for this important clarification. We agree that ESI-MS and HPLC establish the presence/identity of the formulation components but do not, by themselves, establish a specific molecular complex or definitively demonstrate that PTX and DTX are physically embedded within an OCT matrix.
In the original manuscript, the proposed OCT-matrix structure was inferred from the preparation procedure and the physicochemical characterization, and was presented too definitively. The formulation was prepared by dissolving OCT acetate, PTX, and DTX in a 1:1 ethanol/water mixture followed by evaporation of the organic solvent. We therefore agree that the terminology should be revised.
Accordingly, we have changed statements describing the drugs as being definitively “embedded” in an OCT matrix or forming a specific molecular complex to a more appropriate wording "dispersed".
We also agree that the current ESI-MS and HPLC results demonstrate the presence of the three formulation components rather than providing definitive structural evidence for a molecular complex. PXRD, FTIR/Raman spectroscopy, solid-state NMR, quantitative drug recovery/mass balance, and drug-loading measurements would provide stronger evidence regarding the physical state and molecular organization of the formulation. In the revised manuscript, we have clearly stated that this study is a proof-of-concept for the proposed novel formulation, while the suggested analyses have been set as a priority in our future investigations.
- The disappearance of DSC peaks does not by itself prove amorphization or compatibility. PXRD and suitable physical-mixture controls are needed, and the statement that the formulation has “no incompatibility” should be revised.
We fully agree. The original interpretation of the DSC results was overly definitive.
The formulation exhibited no detectable thermal peaks in the investigated temperature range, whereas characteristic thermal events were observed for the individual components. However, as the Reviewer correctly points out, disappearance of thermal transitions may also result from dilution, overlapping transitions, reduced sample concentration, or reduced DSC sensitivity and therefore cannot independently establish amorphization or physicochemical compatibility.
We have therefore revised the relevant text throughout the manuscript. Specifically, we no longer state that the DSC result definitively proves an amorphous state or “no incompatibility.” Instead, we state that:
“The absence of detectable thermal transitions in the final formulation suggests a substantial change in the thermal behavior of the formulation components; however, PXRD and complementary solid-state analyses would be required to definitively establish their physical state and molecular interactions.”
We have also added this issue to the limitations of the study. We agree that P-XRD and physical-mixture controls would substantially strengthen this conclusion and identify these experiments as important future characterization.
- Laser diffraction showed a median diameter of 0.837 µm, whereas TEM showed particles of approximately 200 nm. The authors should clarify the difference and report dispersion conditions, refractive indices, replicate preparations, DLS, zeta potential, and stability data.
We appreciate this comment and agree that the difference requires clearer explanation.
The laser-diffraction analysis showed a bimodal distribution with populations around 0.5 and 1.6 µm and a median diameter of 0.837 µm, whereas TEM visualization showed approximately spherical particles with an apparent diameter of approximately 200 nm. The Supporting Information further reports a median/D50 of 0.837 µm.
We have revised the manuscript to emphasize that these measurements are not directly equivalent measurements. Laser diffraction determines a volume-weighted particle-size distribution in the dispersed state, whereas TEM measures the apparent physical dimensions of dried particles after sample preparation. Aggregation in the aqueous dispersion and/or particle contraction during drying can contribute to the observed difference.
Importantly, we have removed wording implying that the TEM diameter represents the definitive hydrodynamic particle size. We now report the two measurements separately and explicitly state the limitations of comparing them.
We agree that DLS, zeta potential, replicate preparations, complete size distributions, and stability measurements would provide a more comprehensive physicochemical characterization. These analyses were not included in the current study and have therefore been identified as limitations and priorities for future formulation development.
- Visual inspection is insufficient to establish stability of a submicron formulation.
We agree with the Reviewer. The original manuscript described the formulation as homogeneous based partly on the absence of visible aggregates or sedimentation. We acknowledge that visual inspection cannot establish colloidal stability.
We have therefore revised the wording so that visual homogeneity is described only as an initial physical observation, rather than evidence of formulation stability.
We also acknowledge the limitations that systematic stability evaluation involving particle size/PDI, zeta potential, drug content, precipitation, pH, residual solvent, and chemical stability during storage and under physiologically relevant conditions was not performed in the present study. The present study was designed as a proof-of-concept of a novel formulation, rather than a fully stability-qualified pharmaceutical product. Further in-depth investigations and characterization are planned in our future experiments.
- The manuscript claims improved dissolution and potentially controlled delivery, but no release/dissolution study is provided.
We agree with the Reviewer.
The original manuscript inferred potential improvements in dissolution and proposed differential release from the bimodal particle population. However, no direct dissolution or release experiment was performed. Therefore, we have revised such statements to become speculative rather than based on experimental evidence.
We also acknowledge that the absence of release/dissolution data is a limitation. The present study was designed as a proof-of-concept of a novel formulation, rather than a fully-qualified pharmaceutical product. Further in-depth investigations and characterization are planned in our future experiments.
- Free PTX and DTX were prepared in DMSO whereas the formulation was tested in aqueous medium, and the dose basis is not always clear.
We appreciate this important point.
In the original experiments, PTX and DTX were dissolved in DMSO before addition to the culture medium, resulting in a final DMSO concentration below 0.01%, whereas OCT and OCT-PTX-DTX were tested in aqueous form. The manuscript states that this DMSO concentration did not affect cell viability.
We have clarified the experimental description and explicitly state the final DMSO concentration used for the free-taxane controls. We have also clarified throughout the manuscript that concentrations refer to the concentration of the individual taxane(s) rather than simply the total formulation concentration.
We agree that vehicle-matched controls provide the most rigorous comparison. We have therefore identified this as a limitation of the current experimental design and have moderated the interpretation of direct comparisons between free drugs and the aqueous formulation.
- The reported CI values are insufficient to establish synergy because the dose ratio, effect level, confidence intervals, and full dose-response analysis are unclear. Additional controls are recommended.
We thank the Reviewer for this important methodological point.
The current manuscript calculated CI values using the relationship:
CI = (CPTX,50/PTX IC50) + (CDTX,50/DTX IC50)
and reported CI values of 0.4 for HT29 and SW480 and 0.5 for SW620 cells, together with isobologram analyses.
We agree that these data should not be presented as definitive evidence of broad pharmacological synergy across multiple effect levels. The present analysis is specifically based on the IC50 level and does not provide the complete dose-response matrix required for a comprehensive Chou–Talalay assessment across multiple effect levels.
We have therefore revised the terminology to “evidence suggestive of synergistic interaction at the IC50 level” rather than implying definitive synergy across all dose levels.
We have also clarified the dose basis and the limitations of the analysis. We agree that a more rigorous investigation should include multiple fixed PTX:DTX ratios, several effect levels, confidence intervals, and appropriate PTX+DTX combinations without OCT. OCT+PTX and OCT+DTX controls would additionally help distinguish the contribution of OCT-mediated effects from the interaction between the two taxanes, which are planned in our future experiments.
- Increased SSTR1/2 mRNA does not demonstrate receptor-mediated uptake. Surface receptor expression and competition, antagonist, knockdown, and quantitative uptake studies are recommended.
We fully agree with the Reviewer.
The original manuscript inferred receptor-mediated internalization primarily from increased SSTR1/2 mRNA expression following treatment. We recognize that this does not constitute direct evidence of receptor-mediated uptake.
Accordingly, we have substantially revised the mechanistic interpretation. We now describe SSTR1/2 involvement as a proposed targeting mechanism rather than a demonstrated receptor-mediated uptake pathway.
We have modified statements that directly conclude that OCT-PTX-DTX “internalizes via SSTR1/2” based solely on qRT-PCR results. We now state that the observed changes in SSTR1/2 expression are consistent with involvement of somatostatin receptor signaling.
We agree that receptor-binding/competition studies using excess OCT, SSTR antagonists, receptor knockdown, surface receptor quantification, and quantitative intracellular uptake measurements would be required to establish receptor-mediated targeting conclusively. These experiments are now identified as important future investigations.
- The proposed positive feedback mechanism is based only on a single qRT-PCR measurement.
We agree with the reviewer.
The original manuscript proposed that OCT binding induces SSTR upregulation and thereby promotes further internalization. However, our current data only demonstrate changes in SSTR1 and SSTR2 mRNA following treatment and do not establish a temporal feedback loop.
We have therefore modified the interpretation of data to state that the observed changes in SSTR1/2 expression are consistent with involvement of somatostatin receptor signaling.
We also acknowledge that demonstration of such a feedback mechanism would require time-dependent assessment of total and surface SSTR protein, receptor internalization/recycling, and functional uptake, ideally together with receptor inhibition or knockdown experiments, which are planned in our future experiments.
- Sub-G1 accumulation and reduced CDK2/Cyclin A transcripts do not definitively demonstrate apoptosis or functional pathway inhibition.
We agree with the Reviewer.
The present study demonstrated an increase in the sub-G1 population and changes in the mRNA expression of p53, p21, CDK2, and Cyclin A. These observations are consistent with cell-cycle disruption and possible apoptotic progression, but they do not independently establish apoptosis or prove functional inhibition of the p53/p21/CDK2/Cyclin A pathway.
We have therefore revised the manuscript to avoid definitive statements such as “verified apoptosis through the p53/p21 pathway.” The revised text states that the results suggest involvement of p53/p21-associated cell-cycle regulation and apoptotic processes.
We also acknowledge that Annexin V/PI staining, caspase activation, PARP cleavage, protein-level validation, and pathway-specific rescue/inhibitor experiments would be required to establish the proposed mechanism conclusively, which are planned in our future experiments.
- Selectivity is based on only one fibroblast cell line and SSTR expression was not established.
We agree with the Reviewer.
The present study compared three colorectal cancer cell lines (HT29, SW480, and SW620) with one normal human fibroblast model. Although the formulation showed lower cytotoxicity toward MRC-5 cells than toward the cancer cell lines, we agree that this does not establish general tumor selectivity.
In the revised manuscript, we have clarified that this study was designed as a proof-of-concept for the novel formulation, while further in-depth investigations and characterization are planned in our future experiments.
We also acknowledge that SSTR expression was not directly compared between the cancer and normal cells in the present study. Additional normal cell models and quantitative receptor-expression analyses would be necessary to substantiate a receptor-dependent selectivity mechanism, which are planned in our future experiments.
- Claims regarding in vivo tolerability, improved bioavailability, tumor targeting, and clinical translation are not supported by cell-culture data.
We fully agree and appreciate the Reviewer highlighting this issue.
The original manuscript contained statements describing the formulation as “clinically translatable,” “well-tolerated in vivo,” and potentially capable of improving absorption/bioavailability and tumor delivery. We acknowledge that these statements extend beyond the evidence generated in the present study.
We have substantially revised the manuscript to restrict the conclusions to the in-vitro findings demonstrated here. Claims concerning in-vivo tolerability, pharmacokinetics, biodistribution, tumor targeting, systemic bioavailability, hemolysis, and clinical translation have been removed or reframed as potential future applications.
The revised manuscript now emphasizes that the formulation represents an early-stage proof-of-concept requiring pharmacokinetic, biodistribution, toxicity, hemocompatibility, and in vivo efficacy studies before any conclusion regarding clinical translation can be made.
- PTX and DTX share related mechanisms and may produce overlapping toxicities. The rationale for their combination requires stronger justification.
We thank the Reviewer for this valuable point.
Our rationale for combining PTX and DTX was based on the reported potential for combination taxane therapy and the objective of achieving simultaneous delivery of both taxanes while minimizing differences in their delivery profiles. The manuscript currently discusses previous reports of combined PTX/DTX administration and the potential influence of drug-delivery sequence and pharmacokinetics.
Nevertheless, we agree that the rationale and potential limitations of combining two mechanistically related taxanes require clearer discussion.
We have also clarified that the selected formulation composition was investigated as a proof-of-concept and that optimization of the PTX:DTX ratio, comparison with single-taxane formulations, and comparison with clinically relevant taxane delivery systems will be required in future studies.
- The discussion should compare the formulation with established taxane nanocarriers, albumin-bound PTX, polymeric micelles, liposomes, and octreotide-targeted systems and acknowledge limitations.
We agree with the reviewer.
In the revised manuscript, we have clarified that this study has been designed as a proof-of-concept of a novel formulation, in which OCT was used for co-solubilization and targeting of taxanes, which provides a more efficient and tolerable platform compared to commercial methods based on surfactants or organic solvents which have been associated with several toxicities according to literature reports. We plan to compare such a formulation with other established nanoformulations in our future experiments.
Minor Comments
- Title and abstract should specify in-vitro evidence
We agree with the reviewer. The abstract has been revised to make clear that the current work represents an in vitro formulation and biological evaluation and does not establish clinical translation.
The phrase “clinically translatable” has been removed from the abstract/conclusion and replaced with more appropriate proof-of-concept terminology.
- MRC-5 versus MCR-5. The original manuscript incorrectly used “MCR-5” in several locations despite the figure legend referring to MRC-5.
We thank the Reviewer for identifying this typographical error. The correct designation is MRC-5. We have corrected this throughout the manuscript.
- Abstract composition, particle size, IC50 values, limitations
We agree with the reviewer. The abstract has been revised accordingly for a better reflection of the key aspects of the study.
- OCT free base versus acetate
We thank the Reviewer for pointing this out. The material used in the study was octreotide acetate, as specified in the Materials section.
We have revised the formulation description to consistently use octreotide acetate (OCT acetate) where appropriate and clarified the basis of concentration calculations. We have also avoided implying that the formulation contained the free-base form when the starting material was the acetate salt.
- Preparation method
We agree that additional preparation details would improve reproducibility. The current method specifies the initial concentrations of DTX, PTX, and OCT and the 1:1 ethanol/water solvent system, followed by continuous stirring and evaporation of the organic solvent.
We have expanded the Materials and Methods section to provide all experimental details available from the formulation preparation procedure and have clearly indicated any parameters that were not systematically recorded in the original study.
- “Solution” versus “colloidal dispersion”
We agree with the reviewer. Since particle-size analysis and TEM demonstrate the presence of discrete particulate structures, we have replaced “solution” with “colloidal dispersion,” “dispersion,” or “formulation” where scientifically appropriate.
- HPLC validation
We agree that full analytical validation is important, particularly for quantitative drug-loading, recovery, and release studies.
The current HPLC analysis was used primarily to confirm the presence and chromatographic separation of the formulation components. The method parameters currently reported include the C18 column, mobile phases, flow rate, injection volume, temperature, and detection wavelengths.
Because a full validation according to analytical-method validation guidelines was not performed as part of the original study, we have avoided presenting the method as fully validated for quantitative release or mass-balance analysis. We have identified full validation of specificity, linearity, accuracy, precision, recovery, LOD/LOQ, and stability as necessary for future quantitative formulation studies.
- ESI-MS details
We thank the Reviewer. The ESI-MS experimental parameters are now described more clearly, including the instrument, ionization mode, mass range, capillary voltage, source temperature, nitrogen flow, and solvent systems.
We agree that detailed adduct assignment, mass accuracy, calibration information, and systematic matrix-effect assessment would further strengthen the analysis. These have been acknowledged as limitations of the current qualitative ESI-MS characterization.
- Disappearance of DTX ESI-MS peak
We agree completely.
The original manuscript suggested that the disappearance of the DTX peak and transition of the PTX peak could indicate molecular interaction with OCT, while also discussing possible ion suppression.
We have revised this interpretation to avoid assigning a specific molecular interaction to the observed ESI-MS behavior. The disappearance of the DTX signal may arise from ion suppression, altered ionization efficiency, degradation, or sample-preparation effects. Accordingly, we now state that the ESI-MS findings confirm component identity where detectable but do not establish molecular complex formation.
- Particle-size distribution
We agree. The particle size section has been revised to clearly distinguish the differential and cumulative distributions.
The current Supporting Information reports a median/D50 value of 0.837 µm, with a modal diameter of 0.510 µm and D25 and D75 values of 0.505 and 1.701 µm, respectively.
We have clarified the measurement principle and have avoided treating the TEM measurement as equivalent to the laser-diffraction median diameter.
- Proposed sequential drug release
We agree and have removed the speculative statement that the two particle populations necessarily produce sequential PTX/DTX release. No release experiment was conducted to establish this mechanism.
The revised manuscript now states that the bimodal particle-size distribution was observed experimentally but that its consequences for drug-release kinetics remain unknown.
- MTT interference controls
We appreciate this recommendation. We agree that cell-free formulation controls would be appropriate to exclude direct interference of the formulation with MTT reduction or optical-density measurements.
The current study used MTT-based viability measurements, with DMSO used to dissolve the formazan product and as the measurement blank.
We have added this issue to the limitations and have avoided interpreting the MTT results as independent of possible assay-specific interference. A cell-free formulation/MTT control will be included in future validation experiments.
- Cytotoxicity controls
We agree that a comprehensive control design is important. The present study included untreated/vehicle controls, OCT, free PTX, free DTX, and OCT-PTX-DTX.
We have clarified the control groups in the revised Methods and figure legends. We also agree that a formulation-matrix control and additional vehicle-matched controls would further strengthen interpretation and have identified these as desirable controls for future experiments.
- IC50 confidence intervals
we agree that confidence intervals would provide a more complete representation of the IC50 estimates. The cytotoxicity study used multiple concentrations ranging from 0.1 to 200 nM and included the three colorectal cancer cell lines and the normal fibroblast model. A confidence level of 95% was adopted. *P<0.05, **P<0.01, and ***P<0.001 were assumed to be statistically significant. We have clearly stated these statistical criteria, both in the statistical analyses subsection in the Methods section, as well as in the relevant figure legend.
- Selectivity-index calculation
We agree and have clarified the calculation.
The SI was calculated by comparing the IC50 of the formulation in the normal fibroblast model with the corresponding IC50 in each colorectal cancer cell line, as described in the original figure legend.
We have revised the interpretation to state that the SI represents in vitro differential cytotoxicity under the tested experimental conditions and does not constitute evidence of in vivo therapeutic selectivity.
- Figure 4
We thank the Reviewer for this recommendation. Figure 4 and its legend have been revised to clarify that the CI analysis was performed at the IC50 level and to provide the dose basis and experimental replication more explicitly.
We also revised the wording in the Results and Discussion so that the CI values are interpreted as evidence suggestive of synergistic interaction at the tested effect level, rather than as definitive proof of synergy across the entire pharmacological response range. The original study used three independent experiments for the isobologram/CI analysis.
Additional editorial comments
During our checks of the references, we found that the proportion of
self-citations (citations to your own previous work) is relatively high.
While citing relevant previous work by the authors is appropriate and
sometimes necessary, an excessive self-citation rate may give the
impression of bias and may not fully reflect the broader literature in
the field.
We kindly ask you to:
- Carefully review all self-citations and ensure that each one is
essential and directly relevant to the current study; - Reduce non-essential self-citations where possible; and
- Consider adding more references to independent, related studies
to provide a more balanced and comprehensive overview of the existing
We apologize for any inconvenience this may have caused.
In the initial version of manuscript, we may have excessively used self-citations due to our group's numerous and diverse research in this area, and we did not intend to use self-citation irrationally.
In compliance with the editor's recommendation, we have minimized self-citations and added additional independent references to enrich the manuscript and benefit the readers. We have also intended to refer to the original papers reporting the used methodologies as much as we could.
Author Response File:
Author Response.docx
Round 2
Reviewer 3 Report
Comments and Suggestions for AuthorsThe manuscript has been thoroughly revised, and all the comments have been adequately addressed. Thus, the manuscript is accepted for publication in its current form.